{"id":56,"date":"2020-04-22T12:11:52","date_gmt":"2020-04-22T12:11:52","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=56"},"modified":"2020-05-12T05:39:30","modified_gmt":"2020-05-12T05:39:30","slug":"10-april-2020-remdesivir-36-out-of-53-saw-improvements","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/10-april-2020-remdesivir-36-out-of-53-saw-improvements\/","title":{"rendered":"(10 April 2020) Remdesivir &#8211; 36 out of 53 saw improvements"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\"><strong>Compassionate Use of Remdesivir for Patients with Severe Covid-19<\/strong><\/p>\n<p class=\"\">https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2007016<\/p>\n<p class=\"\">In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.)<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Compassionate Use of Remdesivir for Patients with Severe Covid-19 https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2007016 In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/10-april-2020-remdesivir-36-out-of-53-saw-improvements\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(10 April 2020) Remdesivir &#8211; 36 out of 53 saw improvements&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,5],"tags":[25],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/56"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=56"}],"version-history":[{"count":2,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/56\/revisions"}],"predecessor-version":[{"id":62,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/56\/revisions\/62"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=56"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=56"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=56"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}